Free Biopharma Daily Stock Updates - 03/18/21

$XBI $140.49 -5%

Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Pipeline Updates

$GILD -1% & $NOVO -1% Expand clinical collaboration into NASH. source

$CYTK -5% Secondary analysis of GALACTIC-HF will be presented at ACC 21 May 17, 2021. source

$EXEL -1% Clinical collaboration and supply agreement with Merck for ongoing ph 1b study STELLAR-001, adding 3 new cohorts. source

$PGEN -6% FDA grants Orphan Drug Designation for PRGN-2012 for recurrent respiratory papillomatosis. source

$SRNE -6% First patient dosed in ph 1b AL study of STI-6129. source

$ARQT -6% First patient dosed in ph 2a study of ARQ-252 for vitiligo. source

$VTVT -2% Initiates ph 1 study exploring TTP399 in type 1 diabetes. source

$IDRA +2% Pivotal ILLUMINATE-301 study failed to meet primary endpoint. source

$KNSA -3% FDA approval of ARCALYST for recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. The commercial launch is expected in April 2021. source

Financial Updates

$URGN -8% $75M in funding from RTW Investments for tiered royalties on worldwide Jelmyto and UGN-102 sales. source